All In Biotech

Drug Trial Radar · NCT02416167

Study of FYU-981 in Hyperuricemia With or Without Gout

Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study)

Last checked: Nov 19, 2026Latest source record: Feb 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Planned (sponsor's estimate)

Start

May 2015

Primary completion

May 2016

Study completion Nov 2016

Sponsor

Lead sponsor
Fuji Yakuhin Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is confirmatory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 12 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 8 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.

Conditions

  • Hyperuricemia

Interventions

  • FYU-981Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent reduction from baseline in serum urate level at the final visitTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Japan

    Tokyo and Other Japanese City, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.